SBIR/STTR Research Award

Wound Decontamination for the Prevention and Treatment of Multi-drug Resistant Ba

Award identifier 780dd8e1732a3a8c8c70b622978c0613a574e617ad438e31298d811a8cd7bc29Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,638

Program and phase

SBIR · Phase I

Award year

2010

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SYNEDGEN, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
HX79BD6YQ521
Solicitation number
PHS2010-2
Topic code
NIAID

Research abstract

DESCRIPTION (provided by applicant): The frequency of multi-drug resistant infections is increasing at an alarming rate. Equally concerning is the limited therapeutic options available for effective treatment, resulting in increased morbidity and mortality associated with these highly resistant infections. Frequently, multi-drug resistant infections manifest as soft tissue or wound infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other multi-drug resistant bacteria. The proposed project focuses on the development of a non-toxic, topical rinse product. This wound decontaminant is capable of helping to clear bacteria from wound, killing a broad spectrum of resistant and non-resistant bacteria, and providing a residual prophylactic effect that prevents bacterial colonization. By aggregating bacteria, the infectious pathogens are more easily rinsed from the wound. Any bacteria not removed are killed by the polymer derivative and residual material prevents bacterial colonization. This proposed work optimizes the concentration required and specific molecular weight formulation of the molecule to facilitate wound cleaning and protection from subsequent infection. These studies will lead to in vivo studies in Phase II in support of required regulatory applications. The goal is to provide a novel, highly effective and highly biocompatible therapy for the treatment and prevention of wound infections, particularly addressing bacteria that are multi-drug resistant. PUBLIC HEALTH RELEVANCE: A natural antimicrobial polymer derivative has been developed that demonstrates broad-spectrum antibacterial activity against multi-drug resistant and non-resistant bacteria. The polymer is a biocompatible, non-toxic polysaccharide, is not absorbed or metabolized by the body, and is ideal for topical applications. Further, because the mechanism of action of the molecule with bacteria is physical membrane damage, the polymer is less likely to evoke antibiotic resistance. Our aims focus on the characterization and development of a non-toxic, efficacious wound decontamination rinse for prevention and treatment of multi-drug resistant wound infections. The optimized formulation is expected to facilitate the removal of pathogenic bacteria via clumping, reducing the viability of remaining bacteria and providing a limited residual barrier to bacterial colonization. This proposed research is intended to understand and optimize the molecular variables associated with clumping, bactericide and residual effect and ultimately provide a novel therapeutic product to prevent and treat multi-drug resistant wound infections.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

10 SBIR/STTR records share this UEI (2009–2020). Reported award amounts total $4,900,995. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.